Recently, a quinoxaline analog 13-197, a NF-kB and mTOR dual small molecule inhibitor, has been described to inhibit NF-kB and mTOR pathways by targeting the upstream central kinase IKKβ in pancreatic tumor and mantle cell lymphoma in vitro and in vivo [22, 23]. This evidence concerns the gene MTOR and mantle cell lymphoma.